Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Keigo Matsuura"'
Autor:
Toshiyuki Sumi, Motoki Sekikawa, Yuta Koshino, Daiki Nagayama, Yuta Nagahisa, Keigo Matsuura, Naoki Shijubou, Koki Kamada, Keito Suzuki, Takumi Ikeda, Haruhiko Michimata, Hiroki Watanabe, Yuichi Yamada, Koichi Osuda, Yusuke Tanaka, Hirofumi Chiba
Publikováno v:
Thoracic Cancer, Vol 15, Iss 20, Pp 1572-1581 (2024)
Abstract Background The efficacy of anti‐CTLA‐4 antibody (ipilimumab) plus anti‐programmed cell death 1 antibody (nivolumab) in treating advanced non‐small cell lung cancer (NSCLC) is impeded by an elevated risk of severe immune‐related adv
Externí odkaz:
https://doaj.org/article/ce7d0e0952334636b66f0569062931cd
Autor:
Kazuya Takeda, Toshiyuki Sumi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Hiroki Watanabe, Yuichi Yamada, Hirofumi Chiba
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 18, Iss 1, Pp 1-4 (2022)
Abstract Background Biologics dramatically improve symptoms of severe asthma; however, various exacerbating factors may induce flare-up. Pneumocystis spp. have not been reported as a cause of asthma exacerbation during biologic use, although patients
Externí odkaz:
https://doaj.org/article/d80264ecffd740c69d3eb6d3e6499b1f
Autor:
Toshiyuki Sumi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba
Publikováno v:
Thoracic Cancer, Vol 12, Iss 22, Pp 3072-3075 (2021)
Abstract A 66‐year‐old man with squamous cell carcinoma had been receiving chemoradiation therapy after stereotactic radiotherapy for brain metastases. Atezolizumab was initiated as second‐line therapy, after which the patient became progressio
Externí odkaz:
https://doaj.org/article/b19949a1ae4845508d85bac3487a9988
Autor:
Naoki Shijubou, Toshiyuki Sumi, Yoshiko Keira, Hideaki Shiraishi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba
Publikováno v:
Thoracic Cancer, Vol 12, Iss 17, Pp 2407-2410 (2021)
Abstract Pseudocirrhosis is a radiological diagnosis of cirrhosis without histological evidence and occurs as a complication of liver metastases from solid tumors. A 50‐year‐old man without any previous history of liver disease was diagnosed with
Externí odkaz:
https://doaj.org/article/513382e2fa79432086d67d1e2eb1771b
Unexpected haemorrhage from lateral thoracic artery following the removal of a pleural drainage tube
Publikováno v:
Respirology Case Reports, Vol 9, Iss 12, Pp n/a-n/a (2021)
Abstract Pulmonologists must be aware of the possible arterial bleeding even during the removal of a safely inserted drain.
Externí odkaz:
https://doaj.org/article/919a94e3554043349ba65255cf565d16
Autor:
Toshiyuki Sumi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba
Publikováno v:
Respirology Case Reports, Vol 9, Iss 11, Pp n/a-n/a (2021)
Abstract Immune checkpoint inhibitors (ICIs) have been used for various carcinomas. However, immune‐related adverse events have been observed. There have been few reports of treatment with biologics for severe bronchial asthma induced by ICI; there
Externí odkaz:
https://doaj.org/article/92bf677d4f2441bbad1653dbb34a35a6
Autor:
Toshiyuki Sumi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba
Publikováno v:
Respirology Case Reports, Vol 9, Iss 10, Pp n/a-n/a (2021)
Key message Clinicians should be aware that biologic agents, which include polysorbates, can cause delayed local skin reactions at a previous injection site.
Externí odkaz:
https://doaj.org/article/ceed96789cf14f0ba2815e082550439f
Autor:
Motoki Sekikawa, Toshiyuki Sumi, Yoshimatsu Ehama, Ryota Kawamura, Kazuya Takeda, Yuta Nagahisa, Keigo Matsuura, Hiroki Watanabe, Yuichi Yamada, Hirofumi Chiba
Publikováno v:
Haigan. 62:1021-1025
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8e058c053f360888acd4443f7b06c76
https://doi.org/10.2482/haigan.62.1021
https://doi.org/10.2482/haigan.62.1021
Autor:
Toshiyuki, Sumi, Motoki, Sekikawa, Yuta, Nagahisa, Keigo, Matsuura, Naoki, Shijubou, Koki, Kamada, Hiroki, Watanabe, Yuichi, Yamada, Yusuke, Tanaka, Hirofumi, Chiba
Publikováno v:
Investigational New Drugs. 40:1315-1321
Compared to chemotherapy alone, monoclonal antibodies like ipilimumab and nivolumab, with or without chemotherapy, improve the prognosis of patients with non-small cell lung cancer (NSCLC), albeit with a higher incidence of immune-related adverse eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d61f301628c03f79491cfad0829504
https://doi.org/10.1007/s10637-022-01305-8
https://doi.org/10.1007/s10637-022-01305-8
Autor:
Toshiyuki, Sumi, Yuta, Koshshino, Motoki, Sekikawa, Yuta, Nagahisa, Keigo, Matsuura, Naoki, Shijubou, Koki, Kamada, Hiroki, Watanabe, Haruhiko, Michimata, Daiki, Nagayama, Yusuke, Tanaka, Yuichi, Yamada, Hirofumi, Chiba
Publikováno v:
Investigational New Drugs. 40:1298-1305
Pembrolizumab treatment is associated with a favorable prognosis in patients with non-small-cell lung cancer (NSCLC). Here, we investigated the associations among pre-treatment clinical factors, baseline overall tumor burden, and development of sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680e41d602aefa9d5e6c156344efbd1e
https://doi.org/10.1007/s10637-022-01310-x
https://doi.org/10.1007/s10637-022-01310-x